Skip to main content
. 2019 Apr;11(4):1145–1154. doi: 10.21037/jtd.2019.04.56

Figure 2.

Figure 2

A comparison of the overall survival according to the treatment group in all-stage patients (A), stage I patients (B) and stage II and III patients (C). A significant difference in the survival was observed between the groups (log-rank: A: P<0.01, B: P<0.01, C: P<0.01). HGNEC, high-grade neuroendocrine carcinoma; OS, overall survival; HR, hazard ratio; CI, confidence interval.